Third-generation EGFR Tyrosine Kinase Inhibitor
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Third-generation EGFR Tyrosine Kinase Inhibitor, covering 2024-09-05 to 2024-09-05. Get the full timeline:
Most recent: Clinical Trial Update: Clinical Trial of TQB2928 in Combination With a Third-Generation Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) in Patients With Advanced Non-Small Cell Lung Cancers [Phase 1]